GFP Reporter Cell Line - LL/2 (LLC1)

Since its discovery in 1951 by Dr. Margaret Lewis, the LLC (Lewis Lung Carcinoma) cell line has played a pivotal role in oncological research. Initially derived from a lung carcinoma in a C57BL mouse strain, LLC cells have emerged as a cornerstone model for investigating various aspects of cancer biology, metastasis, and therapeutic strategies. Through meticulous characterization efforts spanning several decades, researchers have meticulously unraveled the molecular and phenotypic intricacies of LLC cells, substantially advancing our comprehension of tumor progression and immunotherapeutic responses.

Concurrently, the advent of GFP (Green Fluorescent Protein) reporter cell lines has heralded a revolution in cellular imaging and molecular biology. Integration of GFP into LLC cells has revolutionized the visualization and tracking of intricate cellular processes, encompassing gene expression, protein localization, and cell migration dynamics. This groundbreaking technique, spearheaded by Shimomura, Chalfie, and Tsien in the 1990s, has exponentially augmented the applicability of LLC cells in dissecting complex biological mechanisms. The amalgamation of LLC cells' robustness with GFP reporter technology has empowered researchers to probe deeper into the dynamic interplay between tumor cells and their microenvironment.